Research
Hormonal
Replacing saturated fat with monounsaturated fat (MUFA) or polyunsaturated fat (PUFA) improves insulin sensitivity and lowers fasting insulin concentrations compared to saturated fat diets.
To improve how your body handles insulin, replace saturated fats (butter, fatty meats) with unsaturated fats (olive oil, nuts). This substitution is likely to improve insulin sensitivity and lower fasting insulin levels compared to a high-saturated-fat diet.
GoodSupportsHIGH confidence
Beneficial effect of MUFA both on insulin sensitivity and fasting plasma/serum insulin concentration was considered as probable in comparisons of MUFA and carbohydrates versus SFA...
Why this rating
Graded as 'probable (moderate)' evidence.
Source
Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review
Ursula Schwab et al. · Food & Nutrition Research · 2014
DOI 10.3402/fnr.v58.25145
systematic_reviewCited 375×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Partial replacement of saturated fatty acids (SFA) with polyunsaturated (PUFA) or monounsaturated fatty acids (MUFA) significantly lowers fasting total and LDL cholesterol concentrations.Strong
- Partial replacement of saturated fat with polyunsaturated fat (PUFA) decreases the risk of cardiovascular disease (CVD), particularly in men.Strong
- Fish oil (n-3 LCPUFA) supplementation lowers serum triglyceride (TAG) concentrations compared to monounsaturated fat (MUFA) sources.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →